X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs SUN PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES SUN PHARMA DIVIS LABORATORIES/
SUN PHARMA
 
P/E (TTM) x 38.2 38.0 100.5% View Chart
P/BV x 6.2 4.2 146.9% View Chart
Dividend Yield % 0.7 0.5 132.9%  

Financials

 DIVIS LABORATORIES   SUN PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
SUN PHARMA
Mar-17
DIVIS LABORATORIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,142842 135.6%   
Low Rs533572 93.1%   
Sales per share (Unadj.) Rs146.6131.6 111.4%  
Earnings per share (Unadj.) Rs33.032.7 101.0%  
Cash flow per share (Unadj.) Rs38.438.0 101.1%  
Dividends per share (Unadj.) Rs10.003.50 285.7%  
Dividend yield (eoy) %1.20.5 241.3%  
Book value per share (Unadj.) Rs222.8152.7 145.9%  
Shares outstanding (eoy) m265.472,399.26 11.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.75.4 106.3%   
Avg P/E ratio x25.321.6 117.2%  
P/CF ratio (eoy) x21.818.6 117.1%  
Price / Book Value ratio x3.84.6 81.1%  
Dividend payout %30.310.7 282.8%   
Avg Mkt Cap Rs m222,3181,696,877 13.1%   
No. of employees `00010.817.5 61.4%   
Total wages/salary Rs m4,56149,023 9.3%   
Avg. sales/employee Rs Th3,616.018,028.3 20.1%   
Avg. wages/employee Rs Th423.82,798.8 15.1%   
Avg. net profit/employee Rs Th814.94,479.5 18.2%   
INCOME DATA
Net Sales Rs m38,915315,784 12.3%  
Other income Rs m1,1346,232 18.2%   
Total revenues Rs m40,049322,016 12.4%   
Gross profit Rs m12,617100,893 12.5%  
Depreciation Rs m1,42512,648 11.3%   
Interest Rs m133,998 0.3%   
Profit before tax Rs m12,31390,479 13.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,54312,116 29.2%   
Profit after tax Rs m8,77078,462 11.2%  
Gross profit margin %32.431.9 101.5%  
Effective tax rate %28.813.4 214.9%   
Net profit margin %22.524.8 90.7%  
BALANCE SHEET DATA
Current assets Rs m45,351329,537 13.8%   
Current liabilities Rs m6,507178,870 3.6%   
Net working cap to sales %99.847.7 209.2%  
Current ratio x7.01.8 378.3%  
Inventory Days Days12779 160.4%  
Debtors Days Days9583 114.3%  
Net fixed assets Rs m21,160204,766 10.3%   
Share capital Rs m5312,399 22.1%   
"Free" reserves Rs m58,625363,997 16.1%   
Net worth Rs m59,156366,397 16.1%   
Long term debt Rs m014,361 0.0%   
Total assets Rs m67,832614,102 11.0%  
Interest coverage x926.823.6 3,922.0%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.5 111.6%   
Return on assets %12.913.4 96.4%  
Return on equity %14.821.4 69.2%  
Return on capital %20.824.8 83.9%  
Exports to sales %00-   
Imports to sales %21.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,35944,118 73.3%   
Fx outflow Rs m9,04224,484 36.9%   
Net fx Rs m23,31719,634 118.8%   
CASH FLOW
From Operations Rs m7,75970,822 11.0%  
From Investments Rs m-4,783-42,216 11.3%  
From Financial Activity Rs m-3,142-22,854 13.7%  
Net Cashflow Rs m-1666,107 -2.7%  

Share Holding

Indian Promoters % 52.0 63.7 81.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 5.1 230.0%  
FIIs % 19.0 23.0 82.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 8.3 207.2%  
Shareholders   31,796 133,026 23.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SANOFI INDIA  ABBOTT INDIA  PLETHICO PHARMA  WYETH LTD  GSK PHARMA  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY19); Net Profit Up 50.8% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 50.8% YoY). Sales on the other hand came in at Rs 10 bn (up 21.2% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 18, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS